ATE470443T1 - Indol-1-yl-essigsäurederivate - Google Patents
Indol-1-yl-essigsäurederivateInfo
- Publication number
- ATE470443T1 ATE470443T1 AT05715820T AT05715820T ATE470443T1 AT E470443 T1 ATE470443 T1 AT E470443T1 AT 05715820 T AT05715820 T AT 05715820T AT 05715820 T AT05715820 T AT 05715820T AT E470443 T1 ATE470443 T1 AT E470443T1
- Authority
- AT
- Austria
- Prior art keywords
- indol
- acid derivatives
- compounds
- preparation
- pharmaceutical compositions
- Prior art date
Links
- -1 INDOL-1-YL Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- WQJFIWXYPKYBTO-UHFFFAOYSA-N indole-1-acetic acid Chemical class C1=CC=C2N(CC(=O)O)C=CC2=C1 WQJFIWXYPKYBTO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2004002492 | 2004-03-11 | ||
| PCT/EP2005/002418 WO2005094816A1 (en) | 2004-03-11 | 2005-03-08 | Indol-1-yl-acetic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE470443T1 true ATE470443T1 (de) | 2010-06-15 |
Family
ID=34961431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05715820T ATE470443T1 (de) | 2004-03-11 | 2005-03-08 | Indol-1-yl-essigsäurederivate |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7897788B2 (de) |
| EP (1) | EP1740171B1 (de) |
| JP (1) | JP4861976B2 (de) |
| KR (1) | KR101165863B1 (de) |
| CN (1) | CN1929834B (de) |
| AT (1) | ATE470443T1 (de) |
| AU (1) | AU2005229522A1 (de) |
| BR (1) | BRPI0508579A (de) |
| CA (1) | CA2558545C (de) |
| DE (1) | DE602005021770D1 (de) |
| ES (1) | ES2345662T3 (de) |
| RU (1) | RU2376286C2 (de) |
| WO (1) | WO2005094816A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8958917B2 (en) * | 1998-12-17 | 2015-02-17 | Hach Company | Method and system for remote monitoring of fluid quality and treatment |
| US7417040B2 (en) * | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| KR100808742B1 (ko) | 2004-03-11 | 2008-02-29 | 액테리온 파마슈티칼 리미티드 | 테트라하이드로피리도인돌 유도체 |
| CN101052397B (zh) * | 2004-08-26 | 2011-07-06 | 埃科特莱茵药品有限公司 | 2-硫烷基-苯并咪唑-1-基-乙酸衍生物 |
| AU2005320964B2 (en) | 2004-12-27 | 2011-12-15 | Actelion Pharmaceuticals Ltd. | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
| US7999119B2 (en) | 2006-07-22 | 2011-08-16 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| NZ574705A (en) | 2006-08-07 | 2011-12-22 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
| KR100795462B1 (ko) * | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| PT2250161E (pt) | 2008-01-18 | 2014-01-21 | Atopix Therapeutics Ltd | Compostos tendo atividade antagonista de crth2 |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| EP2558447B1 (de) | 2010-03-22 | 2014-09-17 | Actelion Pharmaceuticals Ltd. | 3-(heteroaryl-amino-)1,2,3,4-tetrahydro-9h-carbazol-derivate und ihre verwendung als prostaglandin-d2-rezeptormodulatoren |
| CN103459371A (zh) * | 2011-04-02 | 2013-12-18 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| MX338516B (es) | 2011-04-14 | 2016-04-20 | Actelion Pharmaceuticals Ltd | Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina. |
| US9242962B2 (en) * | 2011-11-04 | 2016-01-26 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| CN104114169A (zh) | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
| KR102057366B1 (ko) * | 2012-10-15 | 2019-12-18 | 에피자임, 인코포레이티드 | 치환된 벤젠 화합물 |
| KR101864060B1 (ko) | 2014-03-17 | 2018-06-01 | 이도르시아 파마슈티컬스 리미티드 | 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 그의 용도 |
| AU2015233046A1 (en) | 2014-03-18 | 2016-11-03 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
| KR20180053345A (ko) | 2015-09-15 | 2018-05-21 | 이도르시아 파마슈티컬스 리미티드 | 결정질 형태 |
| CN108101829B (zh) * | 2017-11-19 | 2020-05-12 | 华南理工大学 | 一种吲哚化合物、其制备方法及应用 |
| GB202102494D0 (en) * | 2021-02-22 | 2021-04-07 | Amphista Therapeurics Ltd | Novel bifunctional molecules for targeted protein degredation |
| JP2024505328A (ja) * | 2020-12-18 | 2024-02-06 | アンフィスタ セラピューティクス リミテッド | 標的化されたタンパク質分解のための新規の二官能性分子 |
| CN113121543B (zh) * | 2021-04-26 | 2022-03-15 | 重庆理工大学 | 一种吖庚环并[4,5-b]吲哚化合物的制备方法 |
| CN113135907B (zh) * | 2021-04-28 | 2022-02-22 | 山东大学 | 一种提高α-微管蛋白乙酰化水平的化合物及其制备方法与应用 |
| CN117343045A (zh) * | 2023-09-14 | 2024-01-05 | 南方医科大学 | 一种2-(吡啶/喹啉-2-基)-3-(1h-吲哚-3-基)丙酸酯化合物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2171446C (en) | 1993-09-09 | 2004-11-23 | Donald James Kyle | Pseudo- and non-peptide bradykinin receptor antagonists |
| AU752005B2 (en) * | 1998-03-26 | 2002-09-05 | Shionogi & Co., Ltd. | Indole derivatives with antiviral activity |
| DK1115704T3 (da) | 1998-09-25 | 2003-09-29 | Boehringer Ingelheim Pharma | Substituerede indolinoner med inhiberende virkning for forskellige kinaser og cyclin/CDK komplekser |
| IT1315267B1 (it) * | 1999-12-23 | 2003-02-03 | Novuspharma Spa | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale |
| GB0003397D0 (en) * | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
-
2005
- 2005-03-08 BR BRPI0508579-9A patent/BRPI0508579A/pt not_active IP Right Cessation
- 2005-03-08 RU RU2006135652/04A patent/RU2376286C2/ru not_active IP Right Cessation
- 2005-03-08 ES ES05715820T patent/ES2345662T3/es active Active
- 2005-03-08 JP JP2007502265A patent/JP4861976B2/ja not_active Expired - Fee Related
- 2005-03-08 DE DE602005021770T patent/DE602005021770D1/de not_active Expired - Lifetime
- 2005-03-08 US US10/598,781 patent/US7897788B2/en not_active Expired - Fee Related
- 2005-03-08 AT AT05715820T patent/ATE470443T1/de not_active IP Right Cessation
- 2005-03-08 CN CN2005800074945A patent/CN1929834B/zh not_active Expired - Fee Related
- 2005-03-08 KR KR1020067018788A patent/KR101165863B1/ko not_active Expired - Fee Related
- 2005-03-08 EP EP05715820A patent/EP1740171B1/de not_active Not-in-force
- 2005-03-08 CA CA2558545A patent/CA2558545C/en not_active Expired - Fee Related
- 2005-03-08 AU AU2005229522A patent/AU2005229522A1/en not_active Abandoned
- 2005-03-08 WO PCT/EP2005/002418 patent/WO2005094816A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2376286C2 (ru) | 2009-12-20 |
| BRPI0508579A (pt) | 2007-08-14 |
| KR101165863B1 (ko) | 2012-07-13 |
| US7897788B2 (en) | 2011-03-01 |
| EP1740171A1 (de) | 2007-01-10 |
| AU2005229522A1 (en) | 2005-10-13 |
| EP1740171B1 (de) | 2010-06-09 |
| KR20060130211A (ko) | 2006-12-18 |
| CA2558545A1 (en) | 2005-10-13 |
| WO2005094816A1 (en) | 2005-10-13 |
| JP4861976B2 (ja) | 2012-01-25 |
| CN1929834B (zh) | 2010-12-08 |
| CN1929834A (zh) | 2007-03-14 |
| CA2558545C (en) | 2012-10-16 |
| RU2006135652A (ru) | 2008-04-20 |
| JP2007527883A (ja) | 2007-10-04 |
| DE602005021770D1 (de) | 2010-07-22 |
| ES2345662T3 (es) | 2010-09-29 |
| US20070208004A1 (en) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
| NO20073059L (no) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| NO20092529L (no) | Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| NO20051102L (no) | Sulfonylamino-eddiksyre-derivater | |
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| WO2005004818A3 (en) | Heterocyclic compounds and their use as anticancer agents | |
| SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
| CY1108794T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| DE502005008971D1 (de) | Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht | |
| MXPA05011497A (es) | Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace). | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| NO20082848L (no) | Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre | |
| NO20090067L (no) | Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer | |
| TW200621773A (en) | Bicyclononene derivatives | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| TW200628468A (en) | Bicyclononene derivatives | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| TW200621774A (en) | Bicyclononene derivatives | |
| PL1668021T3 (pl) | Nowe związki tioksylozy, sposób ich przygotowania, zawierające je kompozycje farmaceutyczne i ich zastosowanie w lecznictwie | |
| WO2006021399A3 (en) | Azabicyclononene derivatives as renin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |